Non-small cell lung cancer stage I

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
3 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Antibody-drug conjugate (ADC) 1 substance
Unknown / small molecule 1 substance
Phase III: 1 Phase I (Other): 2

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • AstraZeneca AB Commercial
    DATOPOTAMAB DERUXTECAN; RILVEGOSTOMIG
    2024-512195-35-00 9 countries n=119
    Pending

Phase I (Other)

2 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2024-511030-12-00 3 countries 2025 n=17
    Ended
  • Systimmune Inc. Commercial
    IMP not specified
    2023-506539-14-00 3 countries 2025 n=95
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I (Other) 0
Systimmune Inc. Commercial 1 Phase I (Other) 1
AstraZeneca AB Commercial 1 Phase III 0
New trials by year
2025
2
← All indication landscapes